Abstract
Purpose Temporally feathered radiation therapy (TFRT) for head-and-neck cancer (HNC) radiotherapy combines variable-dose daily subplans to increase the rest time of organs-at-risk (OARs) as sought in intensity modulated radiation therapy (IMRT). While the standard TFRT recommends uniform rest time for each OAR, improved toxicity outcomes may be achieved through variable rest time for OARs by incorporating the OARs’ variable radiosensitivity profiles.
Methods and Materials A decision-making model was constructed to maximize the combined recovery of OARs by determining OARs’ optimal rest times. Two main components were incorporated: the cumulative biologically effective dose based on the linear-quadratic model; and a dynamical model capturing the adjusted recovery of OARs as a function of delivered dose. Further, variable radiosensitivity profiles were allowed across the OARs to capture their variable recovery time. Individual recoveries of each OAR under IMRT and the standard TFRT (sTFRT) was compared against optimized TFRT (oTFRT).
Results Five OARs (larynx, esophagus, parotid, spinal cord, brainstem) were considered. When the cumulative dose delivered under TFRT and IMRT remains the same, three OARs exhibited higher recovery under oTFRT compared to the second-best approach (larynx (81.8% vs. 74.1%), esophagus (95.9% vs. 93.9%), parotid (85.6% vs. 83.5%), while the recovery of spinal cord (90.5% vs. 90.8%) and brainstem (96.2% vs. 96.6%) remained comparable under TFRT and IMRT approaches. With different cumulative dose under TFRT and IMRT, oTFRT achieved significantly higher recovery for larynx (95.5% vs. 81.8%) and parotid (92.9% vs. 85.6%), while it is slightly outperformed by IMRT for esophagus (93.4% vs. 95.9%), spinal cord (87.1% vs. 90.5%), and brainstem (90.2% vs. 96.6%). When considering the minimum end-of-treatment recovery, oTFRT always achieved higher recovery among the other two approaches.
Conclusions By considering non-identical radiosensitivity profiles of OARs in HNC radiotherapy, TFRT can optimize their rest time to enhance recovery at the end of treatment, potentially reducing patient toxicities.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding Statement: Clifton D. Fuller and Andrew J. Schaefer have received related grant funding and program support from the National Science Foundation (NSF)/National Institutes of Health (NIH) National Cancer Institute (NCI) Smart and Connected Health (SCH) Program (R01CA257814). Clifton D. Fuller has received grant funding from NIH National Institute of Dental and Craniofacial Research (NIDCR) Academic-Industrial Partnership (R01DE028290), and NIH NCI MD Anderson Cancer Center Support Grant (CCSG) Image-Driven Biologically-informed (IDBT) Program (P30CA016672). Clifton D. Fuller has additionally received related travel, honoraria, and/or registration fee waivers from Elekta AB, with further unrelated travel, honoraria, and/or registration fee waivers from institutions such as the American Society for Radiation Oncology and the Radiological Society of North America. Clifton D. Fuller has also received direct industry grant support, in-kind contributions, and honoraria from Elekta AB and collaborated in an unrelated consulting capacity with Varian/Siemens Healthineers, Philips Medical Systems, and GE Healthcare. Kristy K. Brock has received support from the NIH NCI through the Image Guided Cancer Therapy Research Program at MD Anderson Cancer Center (P30CA016672) and through a licensing agreement with RaySearch Laboratories AB. Lucas B. McCullum was supported by the National Institutes of Health (NIH) National Cancer Institute (NCI) Supplement program under R01CA257814-02S2. Raul Garcia was supposed by the NIH/NCI Supplement program under R01CA257814-02S1.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† Author Responsible for Statistical Analysis: Mehdi Hemmati, PhD (soheil.hemmati{at}ou.edu)
Conflict of Interest Statement: The authors declare no conflicts of interest.
Funding Statement: Clifton D. Fuller and Andrew J. Schaefer have received related grant funding and program support from the National Science Foundation (NSF)/National Institutes of Health (NIH) National Cancer Institute (NCI) Smart and Connected Health (SCH) Program (R01CA257814). Clifton D. Fuller has received grant funding from NIH National Institute of Dental and Craniofacial Research (NIDCR) Academic-Industrial Partnership (R01DE028290), and NIH NCI MD Anderson Cancer Center Support Grant (CCSG) Image-Driven Biologically-informed (IDBT) Program (P30CA016672). Clifton D. Fuller has additionally received related travel, honoraria, and/or registration fee waivers from Elekta AB, with further unrelated travel, honoraria, and/or registration fee waivers from institutions such as the American Society for Radiation Oncology and the Radiological Society of North America. Clifton D. Fuller has also received direct industry grant support, in-kind contributions, and honoraria from Elekta AB and collaborated in an unrelated consulting capacity with Varian/Siemens Healthineers, Philips Medical Systems, and GE Healthcare. Kristy K. Brock has received support from the NIH NCI through the Image Guided Cancer Therapy Research Program at MD Anderson Cancer Center (P30CA016672) and through a licensing agreement with RaySearch Laboratories AB. Lucas B. McCullum was supported by the National Institutes of Health (NIH) National Cancer Institute (NCI) Supplement program under R01CA257814-02S2. Raul Garcia was supposed by the NIH/NCI Supplement program under R01CA257814-02S1.
Data Availability Statement: All data generated and analyzed during this study are included in this article (and its supplementary document). The source code is accessible through https://figshare.com/s/adc2470447ea492338c2.
CRediT Statement: Conceptualization: AK, MH, PM, CD, RG, SH, JGS, JEB, HE, ASRM, KKB, AJS, CDF; Methodology: AK, MH, RG, LBM, PM, CD, SH, AJS, CDF; Software: AK, MH; Validation: AK, MH; Formal Analysis: AK, MH, PM, SH; Investigation: AK, MH, RG, JGS, CD, AJS, CDF; Resources: CD, JGS, ASRM, AJS, CDF; Data Curation: AK, MH, CD, ASRM; Writing - Original Draft: AK, MH; Writing - Review & Editing: AK, MH, FN, PM, CD, LBM, RG, SH, JGS, JEB, HE, ASRM, KKB, AJS, CDF; Visualization: AK, MH; Supervision: JGS, ASRM, AJS, CDF; Project Administration: AJS, CDF; Funding Acquisition: AJS, CDF
Data Availability
All data generated and analyzed during this study are included in this article (and its supplementary document). The source code is accessible through https://figshare.com/s/adc2470447ea492338c2.
